Detalhe da pesquisa
1.
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Breast Cancer Res Treat
; 188(1): 77-89, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728524
2.
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
BMC Cancer
; 21(1): 1021, 2021 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521387
3.
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.
Support Care Cancer
; 25(7): 2055-2062, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188447
4.
Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
BMC Cancer
; 21(1): 1191, 2021 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753434
5.
Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.
Future Oncol
; 11(10): 1511-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25963428
6.
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
J Clin Oncol
; : JCO2400144, 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771995
7.
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.
Support Care Cancer
; 21(6): 1613-20, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23299561
8.
Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis.
Cancer Res Treat
; 55(1): 83-93, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344649
9.
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study.
Cancers (Basel)
; 14(18)2022 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139669
10.
Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.
ERJ Open Res
; 4(1)2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29450203
11.
Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.
J Clin Oncol
; 23(13): 2996-3000, 2005 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15860855
12.
Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
Clin Genitourin Cancer
; 14(6): e595-e607, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27283478
13.
Breast cancer with synchronous metastases: trends in survival during a 14-year period.
J Clin Oncol
; 22(16): 3302-8, 2004 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15310773
14.
Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Clin Genitourin Cancer
; 13(3): 231-8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456838
15.
[Management of emesis in cancer patients]. / Prise en charge des nausées et des vomissements chez les patients cancéreux.
Bull Cancer
; 91(5): 403-8, 2004 May.
Artigo
em Francês
| MEDLINE | ID: mdl-15281279
16.
[Overview of epidermal growth factor inhibitors (with the exclusion of ZD1839 and C225)]. / Panorama des inhibiteurs du récepteur du facteur de croissance épidermique (à l'exclusion du ZD1839 et du C225).
Bull Cancer
; 90 Spec No: S213-9, 2003 Nov.
Artigo
em Francês
| MEDLINE | ID: mdl-14763142
17.
[Epidermal growth factor receptor and chemoprevention of epithelial tumor: rationale and development methods]. / Récepteur du facteur de croissance épidermique et chimioprévention des cancers épithéliaux: rationnel et voies de développement.
Bull Cancer
; 90 Spec No: S251-6, 2003 Nov.
Artigo
em Francês
| MEDLINE | ID: mdl-14763148
18.
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Cancer Chemother Pharmacol
; 71(5): 1297-307, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23479136
19.
[The role of paclitaxel in the first line treatment of cancer of the ovary?]. / Place du paclitaxel en traitement de première ligne des cancers de l'ovaire?
Bull Cancer
; 90(3): 202-3, 2003 Mar.
Artigo
em Francês
| MEDLINE | ID: mdl-12803089